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Zellweger cerebro-hepato-renal syndrome is a severe congenital disorder associated with defective peroxisomal
biogenesis. At least 23 PEX genes have been reported to be essential for peroxisome biogenesis in various species,
indicating the complexity of peroxisomal assembly. Cells from patients with peroxisomal biogenesis disorders have
previously been shown to segregate into 12 complementation groups. Two patients assigned to complementation
group G who had not been linked previously to a specific gene defect were confirmed as displaying a cellular
phenotype characterized by a lack of even residual peroxisomal membrane structures. Here we demonstrate that
this complementation group is associated with mutations in the PEX3 gene, encoding an integral peroxisomal
membrane protein. Homozygous PEX3 mutations, each leading to C-terminal truncation of PEX3, were identified
in the two patients, who both suffered from a severe Zellweger syndrome phenotype. One of the mutations involved
a single-nucleotide insertion in exon 7, whereas the other was a single-nucleotide substitution eight nucleotides
from the normal splice site in the 3′ acceptor site of intron 10. Expression of wild-type PEX3 in the mutant cell
lines restored peroxisomal biogenesis, whereas transfection of mutated PEX3 cDNA did not. This confirmed that
the causative gene had been identified. The observation of peroxisomal formation in the absence of morphologically
recognizable peroxisomal membranes challenges the theory that peroxisomes arise exclusively by growth and division
from preexisting peroxisomes and establishes PEX3 as a key factor in early human peroxisome synthesis.
The importance of peroxisomes in mammalian metab-
olism is illustrated by the existence of severe inherited
metabolic diseases caused by the inability to assemble
peroxisomes. Among these peroxisomal biogenesis dis-
orders (PBDs), Zellweger syndrome, neonatal adreno-
leukodystrophy, and infantile Refsum disease repre-
sent a continuum of clinical phenotypes (PBD [MIM
601539]), whereas rhizomelic chondrodysplasia punc-
tata (RCDP [MIM 215100]) is characterized by distinct
clinical features (Wanders 1999). Peroxisomes have long
been thought to arise exclusively by growth and division
of preexisting peroxisomes (Lazarow and Fujiki 1985),
and only recently have alternative hypotheses been pro-
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posed (South and Gould 1999). Proteins required for
peroxisomal assembly are termed “peroxins” and are
encoded by PEX genes. At least 23 peroxins have been
identified in yeast, most of which are conserved among
different eukaryotic organisms (Subramani 1997). In
most cases, defects in PEX genes lead to a disruption of
peroxisomal matrix protein import, whereas various
peroxisomal membrane components are synthesized
and accumulate in peroxisomal membrane remnants
(“ghosts”). PEX3 and PEX19 mutants represent an ex-
ception to this rule, since the corresponding yeast mu-
tants have been shown to lack even these peroxisom-
al ghosts (Baerends et al. 1996; Go¨tte et al. 1998). We
had previously cloned the human orthologue of PEX3
(PEX3 [MIM 603164]) (Kammerer et al. 1998). Evi-
dence suggests that human PEX3 is a peroxisomal as-
sembly protein displaying two transmembrane helices
in the N-terminal half of the protein. Immunofluorescent
microscopy studies indicate that it is an integral
membrane protein, with its C terminus exposed to the
cytosol and with its N terminus facing the intraorga-
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Figure 1 Somatic cell–fusion experiments. Fusion of coculti-
vated fibroblasts was performed using methods described elsewhere
(Roscher et al. 1989). Fusion of fibroblasts from patients PBDG-01
and PBDG-02 with fibroblasts from a patient carrying a PEX19 mu-
tation (PBDJ-01 [Matsuzono et al. 1999]) restored peroxisomes in the
majority of multinucleated cells, as demonstrated by a punctate im-
munofluorescent pattern after staining for catalase. Somatic cell fusion
of fibroblasts from patient PBDG-01 with fibroblasts from patient
PBDG-02 revealed only diffuse cytosolic staining with anti-catalase
antibodies.
nellar space (Kammerer et al. 1998; Soukupova et al.
1999). Despite an extensive search, disease-causing mu-
tations in the human PEX3 gene have not been identified
so far (Muntau et al. 2000).
In somatic cell–fusion experiments, fibroblasts from
patients with PBDs have been shown to segregate into
12 complementation groups (CGs [Shimozawa et al.
1998; Moser 1999]). In this study, we investigated fi-
broblasts from two patients (PBDG-01 and PBDG-02)
previously assigned to CG-G (Gifu University nomen-
clature [Poulos et al. 1995]). CG-G fibroblasts lack per-
oxisomal ghosts, as evidenced by staining with an an-
tibody directed against the human 70-kD peroxisomal
membrane protein, PMP70 (Shimozawa et al. 1998;
Poulos et al. 1995), and are therefore excellent candi-
dates for a PEX3 mutation. To our knowledge, CG-G
is represented so far by only two patients worldwide,
and cell lines from both individuals were available for
this study.
The two male infants from unrelated families were
born to consanguineous Dutch and Italian parents. Pa-
tient 1 (PBDG-01) showed a marked muscular hypo-
tonia at birth. Dysmorphic features included hyperte-
lorism, prominent epicanthic folds, and a high, broad
forehead with a round face. Seizures developed on day
1 but were controlled with treatment. His condition de-
teriorated rapidly, and he died at age 4 mo. Patient 2
(PBDG-02) was cyanotic at birth, markedly hypotonic,
and lacked deep tendon reflexes. He had a prominent
midface and an antimongoloid slant of the palpebral
fissures, ocular hypertelorism, small low-set ears, a
prominent nose, and a high-arched palate. The liver was
enlarged. Seizures developed during the first 20 h. The
child required gavage feeding and died at age 19 d, of
congestive heart failure. The patient’s brother had been
similarly affected and had died at age 15 d. The con-
centrations of very-long-chain fatty acids were elevated
in the plasma and fibroblasts of patients 1 and 2. In
fibroblasts from both patients, the percentage of sedi-
mentable catalase, the rate of oxidation of pristanic acid,
and the activities of both alkyl dihydroxyacetone phos-
phate synthase and dihydroxyacetone phosphate acyl
transferase were all reduced (Poulos et al. 1995). In sum-
mary, the clinical and biochemical features of both pa-
tients correspond to a severe Zellweger syndrome phe-
notype.
By performing somatic cell–fusion experiments (fig.
1), we showed that fusion of cultured fibroblasts from
patient PBDG-01 with cells from patient PBDG-02 did
not rescue peroxisomal biogenesis. This confirms that
the two cell lines were correctly assigned to the same
complementation group and therefore would be ex-
pected to bear mutations in the same gene. By contrast,
fusion of cultured fibroblasts from patients PBDG-01
and PBDG-02 with those from a patient (PBDJ-01) car-
rying a PEX19 mutation (Matsuzono et al. 1999) re-
stored peroxisomal biogenesis. These results indicate
that CG-G and PEX19 mutated cell lines can comple-
ment each other, despite the fact that both phenotypes
are devoid of detectable preexisting peroxisomal mem-
branes.
When analyzed by immunofluorescent microscopy,
both patient cell lines lacked morphologically recogniz-
able PMP-containing peroxisomal membranes (ghosts).
This was demonstrated by the absence of punctate stain-
ing for the PMP adrenoleukodystrophy protein (ALDP;
fig. 2C and D) and the membrane marker protein
PMP70 (data not shown). However, these findings do
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Figure 2 Intracellular localization of PMPs in CG-G cell lines. Indirect immunofluorescence microscopy was performed with fibroblasts
from a healthy control (A, E, I, and M), from a patient with Zellweger syndrome who was assigned to CG-E (B, F, J, and N), and from the
patients PBDG-01 (C, G, K, and O), and PBDG-02 (D, H, L, and P). The cells were stained using rhodamine-labeled antibodies to ALDP, a
PMP (A–D); fluorescein-labeled antibodies to catalase, a peroxisomal matrix protein (E–H); fluorescein-labeled antibodies to PEX14, a PMP
(I–L), or the mitochondrial marker MitoTracker (M–P). In normal fibroblasts, staining with antibodies to ALDP (A), catalase (E), and PEX14
(I) all yielded a punctate pattern, indicating the presence of peroxisomal membranes and intact peroxisomes. Fibroblasts from a patient with
Zellweger syndrome who was assigned to CG-E (PBDE) were stained with antibodies to the PMPs ALDP (B) and PEX14 (J). Note the
colocalization of the punctate patterns, indicating the presence of peroxisomal membranes. These membranes presumably are nonfunctional
peroxisomal ghosts. Incubation with anti-catalase antibodies (F) resulted in a diffuse cytosolic localization, consistent with the absence of intact
peroxisomes. In cells of PBDG-01 (C) and PBDG-02 (D), no ALDP positive particles were visible, indicating the complete absence of morpho-
logically detectable peroxisomal membranes. Incubation with anti-catalase antibodies (G and H) exhibited a diffuse cytosolic pattern, consistent
with the absence of intact peroxisomes. Staining the cells by use of an antibody specific for PEX14 (K and L) reveals a mitochondrial pattern,
as demonstrated by colocalization of PEX14 with MitoTracker (O and P).
not exclude the possibility that some small peroxisomal
vesicles may still exist in the patients’ cells. The lack of
peroxisomal staining was not accompanied by any de-
tectable staining for these PMPs, in either the cytoplasm
or any other cellular compartment. By contrast, fibro-
blasts from a patient with Zellweger syndrome who,
because of the presence of a PEX1 mutation, was as-
signed to CG-E (PBDE), displayed peroxisomal ghosts
on immunofluorescence (fig. 2B and J). On western blot
analysis, the PBDE cells contained an amount of ALDP
similar to that in fibroblasts from a healthy control,
whereas, in the fibroblasts from PBDG-01 and PBDG-
02, ALDP was below the detection limit of our assay
(data not shown). The lack of immunofluorescence for
ALDP and PMP70, as well as the reduced amount of
ALDP shown on western blot analysis, support the hy-
pothesis that these PMPs are degraded rather than mis-
localized. Analysis of the intracellular localization of an-
other unrelated PMP, PEX14, revealed that the fate of
this PMP in PBDG differs from that for ALDP and
PMP70. Despite the lack of morphologically recogniz-
able peroxisomal membrane staining, the patients’ fi-
broblasts gave an unequivocal signal when antibodies to
PEX14 were used, indicating that this protein was mis-
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Table 1
Primers for Mutation Analysis and RT-PCR of the Human PEX3
Gene
METHOD
AND EXON
PRIMER
Name
Sequence
(5′r3′)
Mutation analysis:
1 5′F3 GAGAGCACAGAACGGGACGA
1R CTCTACATATCCCAGACTAGG
2 2FN CTGTGTAGAATTTTTGGTACTC
2RN CAACCGTCAAACAACTTTAC
3 3F GACTCTTGCTAGTTGCTAGC
3R4 CATTGCCTTGAATGCTTTATGC
4 4FN CTGCAGTTATGCTGTGTTGC
4RN GAGTCATCCTAATAGAATGC
5 5F GGATGGTTCATGATTTTACAC
5R CATAGAAATTGTTATCAGG
6 6F CCCGTCATTTCAGATCTTG
6R2 GACAGTGATCAATTCTGTCAG
7 6F CCCGTCATTTCAGATCTTG
7R GTCACTGGTTTCACTAGAAC
8 8F GCAGTTACAGGTGTAAGCAG
8R3 CTTACCTTTCAAGAGACTCAG
9 9FN GTTTCATCATAACCCTGTGC
9RN CCGACCATGTTGTTCAAG
10 10F CAAAGGTAACCACGTTATTACT
10R2 GTTGTTATCTGGAACAAAAAG
11 11FN GTCCTGTGGGGTCATTTCAG
11RN CCTCTCAGCAGAGAATGTAAC
12 12FN CTTAGAGCTGAATTCATCGC
1255R GTATAGGTGATTTACCCAGTG
RT-PCR:
5 404F AGTACTGTGGCTGT
10 957R GAACTCAGCCATATTGTCTAG
11 1062R GATCTGTCCGTTTACTATAGG
12 1120R GCTCCATTGTCAACAGATC
a F p forward; R p reverse.
localized to mitochondria (fig. 2K and L). This finding
is consistent with results from the western blots, inwhich
the abundance of PEX14 in cells from PBDG-01 and
PBDG-02 was not reduced when compared with that in
cells from either a healthy control or from a patient with
PBDE Zellweger syndrome (data not shown). Taken to-
gether, our data are consistent with the hypothesis that,
in mutants lacking peroxisomal membranes, PMPs are
either degraded, as proposed for ALDP and PMP70, or
mislocalized, as shown for PEX14. Mitochondrial mis-
localization of PEX14 has also been reported in PEX19-
deficient fibroblasts (Sacksteder et al. 2000), and a sim-
ilar mitochondrial mislocalization was observed when
PEX3, PEX12, PEX13, PEX11b, or ALDP was over-
expressed in these PEX19-deficient cells (Sacksteder et
al. 2000). In our native PEX3-deficient cell lines, how-
ever, immunofluorescence studies using antibodies to
ALDP did not lead to any detectable staining, neither in
the peroxisomes nor in the mitochondria, cytoplasm, or
any other cellular compartment.
Because the cell lines of the two patients described
above were excellent candidates for a PEX3 mutation,
we performed PEX3 mutation analysis by direct se-
quencing of genomic fragments, using a slight modifi-
cation of the technique described elsewhere (Muntau et
al. 2000). The primer sequences are listed in table 1.
Patient PBDG-01 exhibited an insertion of a thymine in
exon 7, at nucleotide 543 of the coding region (fig. 3B).
This frameshift mutation is expected to result in a trun-
cation of the C-terminal 190 amino acids of the protein
(fig. 5A).
Sequence analysis of patient PBDG-02 did not reveal
any exonic mutation. However, we identified a TrG
transversion in the 3′ acceptor splice site of intron 10.
Although the conserved polypyrimidine stretch in the
wild type corresponds to the consensus sequence (Pad-
gett et al. 1986), the thymine at 8 relative to exon 11
is replaced by a guanine in the patient (fig. 3C). To de-
termine whether the point mutation interferes with cor-
rect splicing, reverse transcription–PCR (RT-PCR) was
performed. A single PCR product was obtained that was
missing the complete 97 bp of exon 11 (fig. 3D and E).
This exon deletion causes a frameshift, with a premature
termination after 3 amino acids, predicting a 56-amino-
acid C-terminal truncation of the protein. Among the
various types of mutations associated with splicing ab-
errations (Krawczak et al. 1992), 3′ splice-site mutations
occur less frequently than 5′ splice-site mutations, and,
in the majority of cases, the invariant AG dinucleotide
is involved. Mutations at positions 3 to 14 of the
splice-site consensus region have rarely been associated
with splicing defects, but instances of mutations at po-
sition 8 that lead to aberrant splicing have been ob-
served (Beldjord et al. 1988). Additional sequencing
analysis confirmed that the PEX3 intronic change was
absent from 50 unrelated healthy individuals (data not
shown). For these reasons, we conclude that the 8
mutation is the cause of the aberrant splicing in the
patient described here.
The mutations identified in patients PBDG-01 and
PBDG-02 each appeared to be present in a homozygous
state, consistent with the consanguinity of both parental
couples. Hemizygosity with a deletion of the second al-
lele, however, cannot be excluded, since parental DNA
was not available.
The functional impact of the identified mutations was
subsequently investigated by complementation studies.
Immunofluorescent microscopy analysis of fibroblasts
from PBDG-01 (fig. 4A–F) and PBDG-02 (fig. 4G–L)
indicated that both cell lines were lacking intact per-
oxisomes, as demonstrated by diffuse staining with an-
tibodies to catalase (fig. 4B andH). Five days after trans-
fection of PBDG-01 and PBDG-02 by wild-type PEX3
cDNA, antibodies to ALDP (fig. 4C and I) and catalase
(fig. 4D and J) showed a punctate pattern in both cell
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Figure 3 Mutation analyses. A, Genomic organization of the human PEX3 gene. Exons are indicated as boxes. B, Exon 7 sequencing
results and predicted protein sequences of a wild-type control (wt) and patient PBDG-01. Note the homozygous thymine insertion (arrow). The
frameshift causes a premature stop two codons after the insertion. C, Genomic sequencing of the exon-intron boundary of a control individual
(wt) and patient PBDG-02. Note the homozygous substitution of a thymine by a guanine in the 3′ splice site of intron 10, at position 8
(arrow). D, PCR amplification of PEX3 fragments from total RNA of PBDG-02 after synthesis of first-strand cDNA by reverse transcription
using primer 1255R (for primer sequences, see table 1). Amplification of a fragment containing exons 5–10 by primers 404F and 957R did not
reveal any difference between the control individual (wt) and the patient (PBDG-02). The fragment containing exons 5–11 amplified by primer
404F and the exon 11–specific primer 1062R could not be amplified from the patient’s cDNA. Amplification of exons 5–12 by primers 404F
and 1120R produced an aberrantly sized PCR product from the patient’s cDNA. E, Sequence analysis of the PCR fragment containing exons
5–12 show that the PEX3 cDNA of patient PBDG-02 is missing 97 bp, which were present in wt PEX3 cDNA. The 97-bp deletion corresponds
to the sequence of exon 11 and leads to direct fusion of exons 10–12. Premature termination of the protein is predicted from the frameshift.
lines, demonstrating rescue of organelle formation. We
also investigated whether the identified PEX3mutations
affect the function of the PEX3 protein. This was par-
ticularly crucial for the splice-site mutation detected in
patient PBDG-02. We generated PEX3 expression vec-
tors for each mutated PEX3 cDNA. The resulting plas-
mids, pcDNA3-PBDG-01 and pcDNA3-PBDG-02, were
transfected into cells from PBDG-01 and PBDG-02, re-
spectively, and the cells were assayed 5 d later by indirect
immunofluorescence. Transfection of the mutated PEX3
constructs failed to restore peroxisomal biogenesis in the
cells (fig. 4E, F, K, and L). In summary, these results
demonstrate that the mutations identified in the PEX3
gene disrupt the function of PEX3.
The observation of peroxisomal rescue despite the ab-
sence of preexisting peroxisomal membranes is at odds
with the favored model of peroxisomal biogenesis, in
which peroxisomes arise exclusively by budding from
and/or fission of preexisting peroxisomal vesicles (La-
zarow and Fujiki 1985). Instead, it lends support to the
existence of an alternative pathway of peroxisome bi-
ogenesis. There is recent evidence from yeast and human
studies that this pathway is likely to involve the inter-
action of three peroxins—namely, PEX3, PEX16, and
PEX19 (South and Gould 1999; Sacksteder et al. 2000).
In this regard, it is interesting to note that restoration
of peroxisomes after expression of PEX3 in the CG-G
fibroblasts occurred very slowly, over several days. The
stepwise nature of peroxisome synthesis in mutants de-
ficient in peroxisomal membranes has been observed
elsewhere, for both a PEX16-deficient cell line (South
and Gould 1999) and a PEX19-deficient cell line (Mat-
suzono et al. 1999), with PMP-containing vesicles be-
coming visible first, followed by import of peroxisomal
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Figure 4 Functional complementation of patient fibroblasts. In untransfected cells from PBDG-01 (A, B) and PBDG-02 (G and H), no
ALDP positive particles were visible (A and G). Incubation with anti-catalase antibodies (B and H) showed a diffuse cytosolic localization. Five
days after transfection with a human PEX3 cDNA vector (pcDNA3.1/Pex3-Myc-His [Kammerer et al. 1998]), punctate patterns for ALDP (C
and I) and catalase (D and J) indicated that these proteins were colocalized either at or within restored peroxisomes. To generate the mutated
PEX3 expression vectors pcDNA3-PBDG-01 and pcDNA3-PBDG-02, RT-PCR was performed using the primers 5′F3 and 1255R, and the
resulting fragments were cloned into pcDNA3. Transfection of the mutant PEX3 cDNA constructs pcDNA3-PBDG-01 and pcDNA3-PBDG-
02 into cells from PBDG-01 (E and F) and PBDG-02 (K and L), respectively, did not lead to restoration of a peroxisomal punctate pattern
with either ALDP (E and K) or catalase (F and L) immunofluorescence. In an additional experiment, transfection efficiency was verified by
cotransfection of pcDNA3-PBDG-01 and pcDNA3-PBDG-02 constructs, with the green fluorescent protein-expression vector pEGFP-N1 (Clon-
tech) as a reporter plasmid (data not shown).
matrix proteins. These findings suggest that peroxisomal
membrane vesicles form prior to the import of matrix
proteins.
How might the PEX3 mutations disrupt early per-
oxisomal biogenesis? The precise role of PEX3 in the
complex processes leading to the assembly of peroxi-
somes remains to be elucidated. If not from preexisting
vesicles, peroxisomes may arise from some other en-
domembranes of the cell (South and Gould 1999). Al-
though not proved, it has been hypothesized that PEX3
may be sorted to the peroxisome via the endoplasmic
reticulum (ER) (Baerends et al. 1996). It was therefore
proposed that PEX3 mediates the early steps of perox-
isome formation from the ER (Baerends et al. 1996;
Kammerer et al. 1998; Kunau and Erdmann 1998; Ti-
torenko and Rachubinski 1998), and mutations in the
PEX3 gene could potentially interfere with this pro-
cess. PEX3 has been shown elsewhere to interact with
PEX19 and PEX16 in yeast (Go¨tte et al. 1998) and in
humans (Soukupova et al. 1999; South and Gould
1999). A PEX3 mutation might lead to disruption of
the interaction between these early peroxins. In yeast,
this protein-protein interplay appears to be a prerequisite
for generation of preperoxisomal structures that can ac-
quire and stabilize newly synthesized PMPs (Hettema et
al. 2000). Thus, a lack of interaction due to a PEX3
mutation could disturb peroxisomal assembly, by lead-
ing to degradation or mislocalization of other PMPs.
To address this question, we performed PEX3-inter-
action studies to see whether a PEX3 mutation could
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Figure 5 PEX3 in vitro binding assays. A, Schematic diagram of wild-type PEX3 and truncated PEX3 of patient PBDG-01. The mutation
in PBDG-01 results in a C-terminally truncated PEX3 protein, whereas predicted transmembrane regions (TM) remain unaffected. B, Pull-down
assays of in vitro–translated PEX3, with immobilized GST-PEX19, performed as described elsewhere (Glo¨ckner et al. 2000). The left-hand gel
was loaded with 10% of the [35S]-methionine-labeled PEX3 translation products used as input for the binding assays. To ensure that even weak
binding of the mutated PEX3 would be detected, the amount of mutated PEX3 was chosen such that it clearly exceeded the amount of wild-
type PEX3 (wt), which was bound by GST-PEX19, whereas no detectable signal was obtained when the interaction of the mutated PEX3 protein
(PBDG-01) with PEX19 was analyzed (central gel). GST alone did not bind to either protein (right-hand gel). Several repetitions of the assay
yielded similar results. C, Construct lacking the first start codon and the following 63 bp of the PEX3 gene (66 bp).We generated this construct
to demonstrate that the molecular weight of the lower band in the PEX3 wild-type lanes (wt) is a result of the utilization of the internal start
codon at position 199 of the coding region. In vitro translation of this construct by the internal start codon yielded a protein corresponding
to the lower band of wild-type PEX3.
lead to a disruption of the interaction between PEX3
and PEX19. For this purpose, we performed a pull-down
assay after in vitro translation of both wild-type PEX3
cDNA and mutated PEX3 cDNA from patient PBDG-
01. In an in vitro binding assay, we investigated the
ability of wild-type PEX3 and the truncated PEX3 pro-
tein from patient PBDG-01 to bind to an immobilized
GST-PEX19 fusion protein (fig. 5B). Wild-type PEX3
eluted from the GST-PEX19 fusion protein yielded a
strong signal, indicating that wild-type PEX3 binds
PEX19. However, no signal was detected when the in-
teraction of mutated PEX3 with PEX19 was analyzed,
despite the use of an excess amount of mutated protein
compared with the wild-type protein. In vitro translation
of the wild-type sequence yielded two proteins of dif-
fering molecular weight (fig. 5B and C). To demonstrate
that the molecular weight of the lower band in the PEX3
wild-type lanes was a result of the utilization of the
internal start codon at position 199 of the coding region,
we generated a construct lacking the first start codon
and the following 63 bp of the PEX3 gene (66 bp). In
vitro translation of this construct by the internal start
codon yields a protein corresponding to the lower band
of wild-type PEX3 (fig. 5C). In summary, results of the
in vitro binding assays reported here are consistent with
the hypothesis that the interaction between mutated
PEX3 and PEX19 is either markedly reduced or absent.
Although this does not necessarily reflect the situation
in vivo, the potential functional impairment might con-
tribute to impaired peroxisomal membrane synthesis in
cells from patient PBDG-01.
The molecular and biochemical evidence shown here
leaves little doubt that PEX3 mutations are responsible
for Zellweger syndrome in CG-G patients. Both patients
display a very severe Zellweger syndrome phenotype,
with all tested peroxisomal functions being deficient. A
correlation between the severity of the clinical phenotype
and biochemical activities such as plasmalogen synthesis
(Roscher et al. 1985; Lazarow and Moser 1995), as well
as the extent of morphological changes such as the num-
ber of residual peroxisomes in tissues (Arias et al. 1985),
has been described elsewhere for patients with PBD.
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Therefore, it is not surprising that we observed a severe
clinical phenotype associated with mutations in the
PEX3 gene, which encodes a protein considered to be
important in the very early steps of peroxisomal
biogenesis.
We have shown that, by expression of wild-type
PEX3, intact peroxisomes are formed in the PEX3 mu-
tant cell lines, which had lacked detectable peroxisom-
al membrane structures. Similar observations have re-
cently been made for human cells bearing mutations in
either PEX16 or PEX19 (Matsuzono et al. 1999; South
and Gould 1999). The combined data provide evidence
for the essential role of these three early peroxins in a
human peroxisome–formation pathway that does not
require morphologically detectable preexisting peroxi-
somal structures. Besides supplying the basis for molec-
ular diagnostics, the identification of PEX3 mutations
in humans provides an important model for elucidation
of a fundamental mechanism in human organelle
biosynthesis.
Note added in proof. While our manuscript was
undergoing final revision, a report by South et al. (2000)
was published that also describes new data relevant to
the mechanisms of PEX3-mediated peroxisome syn-
thesis.
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